4591
vs
N
Nikkei 225
4591
Over the past 12 months, Ribomic Inc has underperformed Nikkei 225, delivering a return of -10% compared to the Nikkei 225's +40% growth.
Stocks Performance
4591 vs Nikkei 225
Performance Gap
4591 vs Nikkei 225
Performance By Year
4591 vs Nikkei 225
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ribomic Inc
Glance View
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 25 full-time employees. The company went IPO on 2014-09-25. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
